Novartis Pharmaceuticals UK LimitedUK Head OfficeFrimley Business Park FrimleyCamberley Surrey GU16 7SR
+44 1276 692255+44 1276 692508Monday - Friday,8:30 - 17:30
Novartis International AGInvestor RelationsP.O. BoxCH-4002 BaselSwitzerland
+41 61 324 79 firstname.lastname@example.org
Novartis UK Press OfficePress Office enquiries only
+44 1276 email@example.com
Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.
For enquiries contact
+44 1276 698 firstname.lastname@example.org
Our Alcon division is committed to the enhancement, preservation and restoration of vision. Watch our short video to find out how the Academy for Eyecare Excellence supports this commitment.
1 June 2015
The National Institute for Health and Care Excellence (NICE) has today issued a Final Appraisal Determination (FAD) recommending secukinumab for use on the NHS as an option for the treatment of adults with severe plaque psoriasis when - they have failed to respond to, are contraindicated to or cannot take standard systemic* therapies.1
23 April 2015
Novartis is delighted to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Promising Innovative Medicine (PIM) designation for its investigational medicine for patients with heart failure (HF) with reduced ejection fraction, LCZ696 (sacubitril/valsartan).
Adverse event reporting
Product Information Leaflets (PILs) for patients
Summary of Product Characteristics (SPC) for Healthcare Professionals